Fluvastatin in combination with RAD significantly reduces graft vascular disease in rat cardiac allografts

Transplantation

Volumn 72, Issue 6, 2001, Pages 989-993

  Gregory, Clare R ^a   Katznelson, Steven ^b   Griffey, Stephen M ^a   Kyles, Andrew E ^a   Berryman, Edwin R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; RAPAMYCIN DERIVATIVE;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOCARDIUM; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RAT; VASCULAR DISEASE;

EID: 0035959965     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200109270-00002     Document Type: Article

References (40)

1. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression
2. Effect of pravastatin on outcomes after cardiac transplantation
3. The effect of pravastatin on acute rejection after kidney transplantation: A pilot study
4. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection
5. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients
6. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease
7. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo
8. Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD
9. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation
10. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: Induction with chimericanti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-[2-hydroxyethyl]-rapamycin
11. Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: Potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment
12. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts
13. Effect of SDZ-RAD on transplant arteriosclerosis in the rat aortic model
14. Effects of rapamycin analog SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model
15. Are there potential non-lipid lowering uses of statins?
16. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro
17. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2
18. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin
19. Recent advances in statins and the kidney
20. Effects of pravastatin on chronic rejection of rat cardiac allografts
21. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase
22. Direct vascular effects of HMG-CoA reductase inhibitors
23. Current perspectives on statins
24. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation
25. SDZ RAD inhibits cold ischemia-induced vascular remodeling
26. Metabolism and drug interactions of 3-hydroxy-3-mehtylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
27. Rapamune® (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
28. Isoprenoids and ras: Potential in chronic rejection
29. New insights into the pharmacodynamic and pharmacokinetic properties of statins
30. A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisolone-treated renal transplant recipients
31. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisolone-treated renal transplant patients
32. Successful heterotopic heart transplantation in the rat
33. Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation
34. Effect of low molecular weight heparin on suppression of chronic graft vascular disease in a rat cardiac model
35. Translational control of p27Kip1 accumulation during the cell cycle
36. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells
37. The Quilty Effect: Current knowledge and clinical implications
38. Endocardial mononuclear cell infiltrates (Quilty Effect) in heterotopic cardiac allografts in rapamycin-treated rats
39. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group
40. Quilty revisited: A ten year perspective